dipyridamole has been researched along with mopidamol in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (59.09) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McElroy, FA; Philip, RB | 1 |
| Gastpar, H | 2 |
| Carrasco, T; De La Cruz, JP; Sánchez de la Cuesta, F; Smith-Agreda, JM; Villalobos, MA | 1 |
| Carrasco, T; de la Cruz, JP; Ortega, G; Sanchez de la Cuesta, F | 1 |
| de la Cruz, JP; Moron, D; Sanchez de la Cuesta, F | 1 |
| Völkl, KP | 1 |
| Agarwal, KC; Buckley, RS; Parks, RE | 1 |
| Agarwal, KC; Dawicki, DD; Parks, RE | 2 |
| Grimová, J; Kacerovská, H; Mamytbeková, A; Rezábek, K; Svobodová, J | 1 |
| Al-Lamee, KG; Bamford, CH; Middleton, IP | 1 |
| Lichtner, R; Wedderburn, N | 1 |
| Macfarlane, DE | 1 |
| Belleville, J; Benveniste, E; Boissel, JP; Dechavanne, M; Leizorovicz, A; Maitre, P; Mathy, B; Sanchini, B; Schbath, J; Ville, D | 1 |
| Ambrus, CM; Ambrus, JL; Gastpar, H | 1 |
| De La Cruz, JP; Palacios, R; Sánchez de la Cuesta, F; Smith-Agreda, JM; Villalobos, MA | 1 |
| de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
| De La Cruz, JP; Ortega, G; Sánchez de la Cuesta, F | 1 |
| Agarwal, KC; Tzanakakis, GN; Vezeridis, MP | 1 |
| Benítez, A; De la Cruz, JP; Gonzalez-Correa, JA; Olveira, C; Sánchez de la Cuesta, F | 1 |
| De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
1 review(s) available for dipyridamole and mopidamol
| Article | Year |
|---|---|
[Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results].
Topics: Animals; Bencyclane; Cell Adhesion; Cells, Cultured; Dipyridamole; Humans; Lymphocytes; Mice; Mopidamol; Neoplasm Metastasis; Pentoxifylline; Phosphorus Radioisotopes; Platelet Aggregation; Pyrazoles; Pyrazolones; Pyrimidines; Rats | 1983 |
1 trial(s) available for dipyridamole and mopidamol
| Article | Year |
|---|---|
Drugs effect on platelet survival time: comparison of two pyrimido-pyrimidine derivatives in patients with aortic or mitral replacement.
Topics: Adult; Aged; Aortic Valve; Blood Platelets; Dipyridamole; Heart Valve Prosthesis; Humans; Middle Aged; Mitral Valve; Mopidamol; Pyrimidines; Time Factors | 1984 |
20 other study(ies) available for dipyridamole and mopidamol
| Article | Year |
|---|---|
Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Blood Platelets; Cyclic GMP; Dipyridamole; Humans; Mopidamol; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Adhesiveness; Platelet Aggregation; Pyrimidines | 1975 |
[Inhibition of the "cancer cell stickiness" using pentoxyphylline (Trental)].
Topics: Animals; Blood Coagulation; Carcinoma 256, Walker; Dipyridamole; Dose-Response Relationship, Drug; Ketones; Mopidamol; Neoplastic Cells, Circulating; Rats; Surface Properties; Xanthines | 1976 |
The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion.
Topics: Animals; Brain; Dipyridamole; Disease Models, Animal; Ischemic Attack, Transient; Lipid Peroxidation; Male; Mitochondria; Mopidamol; Oxidation-Reduction; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Tetrazolium Salts | 1992 |
Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes.
Topics: Animals; Ascorbic Acid; Cardiotonic Agents; Cell Membrane; Dipyridamole; Ferrous Compounds; Humans; Kinetics; Lipid Peroxidation; Liver; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Species Specificity; Vitamin E | 1992 |
Antiplatelet effect of the pyrimido-pyrimidinic derivative RA-642.
Topics: Adenosine; Cardiotonic Agents; Dipyridamole; Dose-Response Relationship, Drug; Humans; Male; Mopidamol; Platelet Aggregation Inhibitors; Pyrimidines; Theophylline | 1991 |
A sensitive in vivo platelet function test in rats based on intravenously injected collagenase.
Topics: Animals; Aspirin; Dipyridamole; Imidazoles; Indomethacin; Injections, Intravenous; Ketanserin; Microbial Collagenase; Mopidamol; Platelet Count; Platelet Function Tests; Rats; Rats, Inbred Strains | 1989 |
Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Adenosine Deaminase; Animals; Blood Platelets; Dilazep; Dipyridamole; Drug Synergism; Humans; Isoquinolines; Male; Mopidamol; Platelet Aggregation; Pyrimidines; Rats; Rats, Inbred Strains; Species Specificity; Tetrahydroisoquinolines | 1987 |
Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Azepines; Biological Transport, Active; Blood Platelets; Cyclic AMP; Dilazep; Dipyridamole; Drug Synergism; Humans; In Vitro Techniques; Mopidamol; Nucleosides; Platelet Aggregation; Pyrimidines | 1986 |
Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors.
Topics: Animals; Antineoplastic Agents; Dipyridamole; Flurbiprofen; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mopidamol; Neoplasm Metastasis; Pentoxifylline; Platelet Aggregation; Propionates; Pyrimidines; Theobromine | 1986 |
Polymeric inhibitors of platelet aggregation. II. Copolymers of dipyridamole and related drugs with N-vinylpyrrolidone.
Topics: Adenosine Diphosphate; Dipyridamole; Humans; Kinetics; Mass Spectrometry; Mopidamol; Platelet Activating Factor; Platelet Aggregation; Polymers; Povidone; Structure-Activity Relationship | 1987 |
Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine.
Topics: Adenosine; Azepines; Blood Platelets; Dilazep; Dipyridamole; Erythrocytes; Humans; In Vitro Techniques; Inosine; Mopidamol; Platelet Aggregation; Thioinosine | 1985 |
Enhancement of the immune response to sheep erythrocytes in mice by phosphodiesterase-inhibiting dipyridamole derivatives.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Dipyridamole; Erythrocytes; Hemolytic Plaque Technique; Immunization; Immunoglobulin M; Male; Mice; Mice, Inbred BALB C; Mopidamol; Pyrimidines; Sheep; Spleen | 1984 |
Inhibitors of cyclic nucleotide phosphodiesterases inhibit protein carboxyl methylation in intact blood platelets.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Dipyridamole; Humans; Hydrogen-Ion Concentration; Hydrolysis; Methionine; Mopidamol; Papaverine; Protein Methyltransferases; Protein O-Methyltransferase; S-Adenosylmethionine | 1984 |
Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations.
Topics: Animals; Bencyclane; Blood Coagulation; Carcinoma 256, Walker; Depression, Chemical; Dipyridamole; Dose-Response Relationship, Drug; Humans; Mopidamol; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Cells, Circulating; Pentoxifylline; Platelet Aggregation; Pyrimidines | 1981 |
In vitro effect of mopidamol on platelet-subendothelium interaction.
Topics: Adult; Cell Communication; Dipyridamole; Endothelium, Vascular; Humans; In Vitro Techniques; Male; Mopidamol; Perfusion; Platelet Aggregation; Platelet Aggregation Inhibitors | 1995 |
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; Lens, Crystalline; Lipid Peroxidation; Male; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Superoxides | 1994 |
Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity.
Topics: Animals; Blood Platelets; Blood Vessels; Cyclooxygenase Inhibitors; Dipyridamole; Enzyme Activation; Epoprostenol; Humans; Lipid Peroxidation; Male; Mopidamol; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Thromboxane A2 | 1994 |
Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.
Topics: Adenosine; Animals; Dipyridamole; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Nude; Mopidamol; Pancreatic Neoplasms; Platelet Aggregation; Tumor Cells, Cultured | 1993 |
Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue.
Topics: Adult; Aged; Animals; Antioxidants; Dipyridamole; Female; Ferrous Compounds; Humans; In Vitro Techniques; Lipid Peroxidation; Lung; Male; Malondialdehyde; Middle Aged; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Vitamin E | 1996 |
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epoprostenol; Male; Mopidamol; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Pyrimidines; Rats; Rats, Wistar; Thromboxanes | 1996 |